Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Must have a Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive.~* Must have a normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) of \> 80 mL/min/1.73 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula and the absence of protein in the urine~For Parts 1 and 2:~• Must be a clopidogrel responder (eg, a decrease in platelet aggregation of at least 30% after a single 600-mg dose of clopidogrel compared with baseline).~Exclusion Criteria:~* Any significant acute or chronic medical illness, including tinnitus or any other condition listed as a contraindication in the aspirin package insert.~* History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for 1 week's duration in the last month prior to study treatment administration).~* History of head injury in the last 2 years, including participants with base skull fractures, intracranial tumor, or aneurysm.~* History of gastroesophageal reflux disease, dyspepsia (indigestion), protracted nausea, or chronic diarrhea (defined as 3 or 4 loose stools per day that last for ≥ 4 weeks) within the past 6 months.~Other protocol-defined inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BMS-986177 + Aspirin + Clopidogrel (Part 1) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
- BMS-986177 (Part 1) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5)
- BMS-986177 placebo + Aspirin + Clopidogrel (Part 1) (Type: PLACEBO_COMPARATOR): BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
- BMS-986177 (Part 2) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5)
- BMS-986177 placebo + Clopidogrel (Part 2) (Type: PLACEBO_COMPARATOR): BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
- BMS-986177 + Clopidogrel (Part 2) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
- BMS-986177 (Part 3) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5)
- BMS-986177 placebo + Aspirin (Part 3) (Type: PLACEBO_COMPARATOR): BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
- BMS-986177 + Aspirin (Part 3) (Type: EXPERIMENTAL): BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete